Fig. 1: PFS and OS of patients with high-grade NENs of GEP or UK origin treated with nivolumab, carboplatin, and etoposide. | Nature Communications

Fig. 1: PFS and OS of patients with high-grade NENs of GEP or UK origin treated with nivolumab, carboplatin, and etoposide.

From: Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

Fig. 1

A Kaplan Meier showing the OS for the full dataset (n = 37). The red line shows the estimated survival proportion and the shadow area the 95% CI. The red dashed lines indicate the 50% survival probability point estimate. B Multivariable analysis to find potential baseline prognostic factors for OS. The forest plot shows the hazard ratio of each subgroup and its 95% CI. C Kaplan-Meier showing the PFS for the full dataset. D Multivariable analysis to find potential baseline prognostic factors for PFS. The forest plot shows the hazard ratio of each subgroup and its 95% CI. Multivariable analyses were performed using the Cox model and are exploratory. Significance tests are two-sided. Source data are provided as a Source Data file. CGA chromogranin A, CI confidence interval, Diff differentiated, ECOG-PS Eastern Cooperative Oncology Group Performance Status, HR hazard ratio, OS overall survival, PFS progression-free survival.

Back to article page